Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) clinical-stage pharmaceutical firm will be discussing 3Q20 financial results with the investment community.on 5th November 2020 at 5:00 PM eastern time.
Those interested in listening to the conference call live via the Internet can visit www.aeriepharma.com
Earnings Expectation
Aerie Pharmaceuticals, Inc. clinical-stage pharmaceutical firm, is reporting third quarter earnings results on Thursday 5th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.8 per share from $ 19.71 million in revenue. For the full year, analysts predict revenues of $ 80.43 million, while looking forward to loss of $ 3.2 per share.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 100.00 million ~ $ 110.00 million
Click Here For More Historical Outlooks Of Aerie Pharmaceuticals, Inc.
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The companys advanced-stage product candidate is Roclatan, a once-daily eye drop to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension.
